About Cytophenix
Transforming infection management with rapid antimicrobial susceptibility testing.
Cytophenix is transforming infection management with rapid antimicrobial susceptibility tests, providing swift, accurate results to identify effective antibiotics and antifungals for each patient. This enhances treatment and combats antimicrobial resistance. Founded by expert researchers, clinicians, clinical laboratory personnel, and engineers, Cytophenix aims to shorten treatment recommendation times, improve outcomes, and save lives by ensuring patients receive the right treatment at the right time, every time.
Why AST Matters
Definitive guidance for antimicrobial treatment decisions requires the AST result, which identifies pathogen susceptibility to guide therapy with clinical confidence. Traditional methods delay results by 48–72 hours, risking lives in the critical first 24 hours of sepsis, where optimal therapy can avoid 80% of negative outcomes. (WHO)5
Directors
Mike Clark
NED
Mr. Michael Clark is an experienced software engineer with a specialisation in applying artificial intelligence to biomedical diagnostics data. As a Non-Executive Director at Cytophenix, he ensures that the company's research and development activities are aligned with commercial objectives and market entry strategies. His expertise in machine learning and data analysis plays a pivotal role in guiding strategic decisions and enhancing the company's technological offerings.
Russell Nicholls
NED — Board Chair
Mr. Russell Nicholls is an experienced board professional with extensive executive and advisory expertise in innovative companies and non-profit organisations, particularly in the biomedical and agri-food tech sectors. His broad knowledge encompasses research and development management, strategy, finance, legal aspects, and governance. As the Non-Executive Chair of Cytophenix, he plays a crucial role in establishing governance structures and aligning the company's strategy with robust financial frameworks, driving significant impact and fostering a strong organisational culture.
Richard Hopkins
NED
Dr. Richard Hopkins is a seasoned bio-pharmaceutical executive with extensive experience in corporate leadership, drug development, and commercialization within the biotechnology sector. With over 20 years of experience, Dr. Hopkins has successfully raised over $40 million AUD in financing and has a proven track record in the development of novel therapies, particularly in oncology and medicinal cannabis. As a Non-Executive Director at Cytophenix, his strategic insights and deep industry knowledge guide the company towards successful market positioning and commercial viability.
Core Operations
Kieran Mulroney
CEO
Dr. Kieran Mulroney is an esteemed leader in the field of microbiology diagnostics with a proven track record in the development, validation, and commercialization of innovative diagnostic tools. With a career foundation in research, particularly focused on personalised precision diagnostics for serious infections, Dr. Mulroney has transitioned his expertise into a strategic and commercial leadership role as the CEO of Cytophenix. His work encompasses managing large-scale, multidisciplinary projects and driving forward the development of new technologies in the medtech sector.
Christine Carson
CSO
Dr. Christine Carson is a seasoned microbiologist and influential researcher with an extensive background in developing novel diagnostic tools, particularly focusing on antimicrobial susceptibility testing. As the Chief Scientific Officer at Cytophenix, Dr. Carson integrates her deep scientific expertise with strategic business acumen to enhance diagnostic practices and contribute to global health solutions, particularly in the realms of sepsis and bacteraemia.
Sherief Khorshid
CTO
Mr. Sherief Khorshid is an accomplished technology leader, blending a strong fintech background with deep expertise in AI and MedTech. As the CTO of Cytophenix Pty Ltd, he spearheads the development of AI-driven medical technologies, enhancing diagnostic precision and patient care. His strategic vision and innovation have been pivotal in integrating cutting-edge AI solutions into healthcare operations, propelling both technological advancement and commercial success in the medical sector.
Peter Bradley
Chief Commercial Officer
Peter Bradley has over 30 years’ experience in innovative product development, diagnostic and medtech business development, and international commercialisation within the executive suite. His responsibilities will include establishing partnerships that will accelerate the commercial development of Cytophenix FloCAST™ and prepare for a successful commercial launch in our target markets. He is currently Managing Director and principal consultant of Qatalyst, a bio-consultancy for commercialization. Previously he has held executive roles as VP Global Business Development at LBT Innovations (now Clever Culture Systems ASX:CC5), Chief Business Development Officer at Innate Immunotherapeutics (now Amplia Therapeutics ASX: ATX), CEO at KODE Biotech (NZ), as well as Non-executive Director at Biosensis.
Teagan Paton
Laboratory Operations
Teagan is a seasoned microbiologist with nearly two decades of experience in diagnostics and research. As the Laboratory Operations Manager at Cytophenix, Teagan specialises in laboratory test integration and enhancing workflow efficiency through advanced data handling techniques. Proficient in big data analysis, data mining, and database management, Teagan plays a pivotal role in the commercialization of innovative medical diagnostics technologies.
Nick Thomson
Data Science
With a BSc in Pure Mathematics from UWA and 12 years commercial experience in Analytics, Machine Learning and programming in C++ and Python, Nick has delivered solutions where he applied computer vision AI in the field of exploration geophysics. Nick is also a highly regarded member of PMLG (Perth Machine Learning Group).
Commercial Advisory
James Telders
Strategic Advisor
Mr. James Telders is a seasoned Chartered Financial Analyst with a profound understanding of financial markets and commercial strategy. Specialising in mergers, acquisitions, and commercialization of technological innovations, Mr. Telders has significantly contributed to the successful validation and commercial launch of several software as a medical device (SaMD) products across international markets. At Cytophenix, he ensures that the research and development efforts align with robust commercial strategies and market needs.
Levi Kirwin
Market Advisor
Nissi Strategy & Marketing's principal consultant, Levi Kirwin has been contracted to provide services to Cytophenix to support marketing and market access activities. An expert in navigating health-system pathways and unlocking adoption at scale, his deep expertise in positioning and market access in key target markets strengthens Cytophenix's commercial strategy. Levi has more than 20 years' experience in clinical diagnostics and medical devices, including roles as Director of Marketing, Clinical Diagnostics at Alexion Pharmaceuticals, Head of Marketing at Accelerate Diagnostics and Marketing Manager at Beckman Coulter, as well as fractional executive roles in med device startups.